Alnylam Pharmaceuticals Leads Biopharma Charge Amid Tariff Uncertainty
Vertex and Alnylam are best positioned among biopharma companies to weather trade tensions, according to Goldman Sachs analyst. Regeneron and Biogen may be more vulnerable due to their reliance on imports.